Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Replacement of potassium in the treatment or prevention of hypokalemia,Fluid and electrolyte replenishment,Correction of dehydration and maintenance of fluid balance
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Intravenous administration at a rate not exceeding 10 m Eq/hour of potassium chloride; typical adult dose is 20-40 m Eq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Potassium has a biphasic elimination: distribution half-life ~1 hour, terminal elimination half-life ~12 hours in normal renal function. Clinical context: Half-life extends significantly in renal impairment, requiring dose adjustment.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium chloride is not metabolized; potassium is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with insulin facilitating cellular uptake.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Minor fecal elimination accounts for ~10%. Renal excretion is influenced by aldosterone, acid-base status, and potassium intake.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Potassium is minimally protein-bound (<5%); binding proteins are not clinically significant as free ion is active.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Vd is approximately 0.5-0.7 L/kg (total body water). This reflects extensive distribution into intracellular compartments, where 98% of total body potassium resides.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Intravenous: 100%. Oral: Approximately 90% absorbed in the small intestine (bioavailability is high but absorption can be affected by gastrointestinal motility and formulation). The 0.075% solution is for IV use only.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
For GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use or use with extreme caution and frequent monitoring.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
In hepatic impairment (Child-Pugh Class B or C): initiate at 50% of typical dose and titrate based on serum potassium levels and electrocardiographic monitoring; no specific adjustment for Child-Pugh A.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
0.5-1 m Eq/kg per day as a continuous intravenous infusion, not to exceed 0.5 m Eq/kg/hour; maximum daily dose 3 m Eq/kg; must be diluted in appropriate IV fluid such as dextrose 5%.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at low end of dosing range (e.g., 10-20 m Eq per day) with careful titration; monitor renal function and serum potassium closely due to age-related decline in glomerular filtration rate.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
None
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or those receiving potassium-sparing diuretics,Monitor serum potassium levels and ECG during administration,Do not administer undiluted potassium chloride; must be diluted in appropriate solutions,Use with caution in patients with cardiac disease or conditions predisposing to hyperkalemia,Rapid infusion may cause hyperkalemia and cardiac arrest
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia,Severe renal impairment with oliguria or anuria,Adrenal insufficiency (e.g., Addison's disease),Acute dehydration,Concurrent use with potassium-sparing diuretics or ACE inhibitors at high risk of hyperkalemia,Conditions causing extensive tissue breakdown (e.g., severe burns, crush injuries) as they may release intracellular potassium
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid potassium-rich foods or supplements unless explicitly prescribed, as this IV already provides potassium. Consult your provider about dietary potassium intake if you are on this infusion. High-potassium foods include bananas, oranges, potatoes, spinach, and salt substitutes.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride and dextrose are not known teratogens. No fetal risk at therapeutic doses. Inadequate data for first trimester, risk cannot be excluded. Second and third trimesters: safe when used as indicated.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium and dextrose are normal components of breast milk. No M/P ratio available. Considered compatible with breastfeeding at therapeutic doses.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustment required for pregnancy. However, increased plasma volume and GFR in pregnancy may alter potassium and glucose homeostasis; monitor levels and adjust accordingly.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
This is a hypotonic potassium solution (K+ 10 m Eq/L) used for maintenance and replacement in patients with hypokalemia who also require dextrose. Monitor serum potassium and glucose, especially in diabetics. Do not administer undiluted; always add to a compatible IV solution. Use with caution in patients with renal impairment, cardiac disease, or those on digoxin due to risk of hyperkalemia. Pain at the infusion site may occur; consider central line administration for concentrations >10 m Eq/100 m L.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
This medication is given through a vein (IV) to provide potassium and sugar to your body.,Tell your healthcare provider if you have any kidney problems, heart disease, or diabetes.,Report any pain, redness, or swelling at the IV site.,You may need regular blood tests to check your potassium and sugar levels.,Do not suddenly stop receiving this treatment without consulting your provider.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL, answered by our medical review team.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous administration at a rate not exceeding 10 m Eq/hour of potassium chloride; typical adult dose is 20-40 m Eq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not known teratogens. No fetal risk at therapeutic doses. Inadequate data for first trimester, risk cannot be excluded. Second and third trimest. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.